Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2021

View Archived Issues

Novel synthetic biotic to promote mucosal healing for treatment of IBD

CIDEC gene silencing ameliorates experimental diabetic cardiomyopathy

Researchers develop new model of extracorporeal membrane oxygenation thrombosis

ADO-09 shown to be superior to insulin aspart in type 1 diabetes patients

ATTR removal observed in vitro and in vivo with NI-006

Encouraging development updates for SupraAntigen-derived liposomal AD vaccine candidates

Centivax enters strategic partnership with NMRC for phase I development of Centi-B9

First patient enrolled in phase Ib study of LB-100 for treatment of small cell lung cancer

Wave Life Sciences presents promising preclinical data for its ADAR editing program

Lophora ApS patents 5-HT2A receptor agonists

Nurix Therapeutics presents new PROTACs

Crinetics Pharmaceuticals synthesizes new melanocortin MC2 receptor antagonists

Merck & Co. identifies nicotinic alpha7 receptor PAMs

Suzhou Zelgen Biosciences synthesizes new GTPase KRAS mutant inhibitors

Phase II results presented from study comparing AZD-9567 versus prednisolone in active RA

Preclinical and early clinical characterization of VIB-7734

Epeleuton shows efficacy in preclinical models of atherosclerosis

New biomarkers identified for diagnosis of Cushing's syndrome

U.K. study identifies another danger of COVID-19: increased antibiotic resistance

Replimune provides updated clinical data for RP-1 and RP-2 programs

Mindset selects its lead next-generation psychedelic candidate, MSP-1014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...